Join
Live feed
·
PRReleasevia Quantisnow
Clovis Oncology Inc. logo

Clovis Oncology's Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3 ATHENA-MONO Trial

ByQuantisnow·Wall Street's wire, on your screen.
CLVS· Clovis Oncology Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CLVS (Clovis Oncology Inc.) and more on Quantisnow.